Xtandi 40 MG capsule 120S
Ended Awarded
- Contract number
- SPE2DR26FSQN3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $25,532
Award facts
- Contract value 100% obligated
- $25,532.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) issued a firm fixed-price delivery order valued at $25,532.04 to DMS Pharmaceutical Group Inc. on November 18, 2025, for the supply of Xtandi 40 mg capsules (120-count units). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order falls under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the DLA, specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499.999 billion ceiling value and completion date of December 31, 2036.
The PPV-G GEN V represents part of DLA's broader $30.3 billion pharmaceutical supply strategy, positioning DMS Pharmaceutical Group as a regional prime vendor contractor authorized to supply branded and generic prescription medications, biologics, and medical consumables to Department of Defense healthcare facilities worldwide. Xtandi, a specialty oncology treatment, aligns with DMS Pharmaceutical Group's established portfolio of high-value pharmaceutical products serving military medical operations. The delivery order has an ultimate completion date of November 19, 2025, with performance to be fulfilled at the contractor's Park Ridge, Illinois location.
Quick answers
Who was awarded contract SPE2DR26FSQN3?
SPE2DR26FSQN3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 18, 2025.
How much is contract SPE2DR26FSQN3 worth?
The government has obligated $25,532 on SPE2DR26FSQN3.
Is contract SPE2DR26FSQN3 an order under another contract?
Yes. SPE2DR26FSQN3 is a delivery order under SPE2DR25D9348, an indefinite delivery contract.
Was contract SPE2DR26FSQN3 competed?
The extent of competition for SPE2DR26FSQN3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award